NCT00557609View on ClinicalTrials.gov

Phase 2 Study in Patients With MiT Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions
Renal Cell Carcinoma (RCC)Alveolar Soft Part Sarcoma (ASPS)Clear Cell Sarcoma (CCS)
Interventions
DRUG

ARQ 197

360 mg administered twice daily until disease progression or other discontinuation criterion is met

Trial Locations (9)

33136

Miami

45229

Cincinnati

75201

Dallas

77030

Houston

90404

Santa Monica

94143

San Francisco

02115

Boston

M5G 2M9

Toronto

SW3 6JJ

London

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00557609 - Phase 2 Study in Patients With MiT Tumors | Biotech Hunter | Biotech Hunter